Moviprep

Polyethylene glycol, the active ingredient in Moviprep, is an osmotic laxative presented as a powder for oral solution for oral use. It is employed to cleanse the bowel before colonoscopy or sigmoidoscopy in adult patients, facilitating safe and effective endoscopic examination.

GNH USA supplies Moviprep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moviprep is an osmotic laxative used for bowel cleansing in endoscopic procedures.

Colonoscopic preparation: provides thorough bowel evacuation to enable clear visualization during colonoscopy. Sigmoidoscopic preparation: cleanses the distal colon to improve image quality for sigmoidoscopy. Pre‑procedure bowel cleansing: reduces fecal residue, decreasing the risk of missed lesions during endoscopic evaluation.

Moviprep may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate feeling of queasiness. - Abdominal bloating: sensation of fullness or distension. - Cramping: intermittent abdominal pain. - Vomiting: occasional expulsion of stomach contents. - Headache: mild tension‑type headache. - Electrolyte imbalance (mild): temporary changes in sodium or potassium levels.

Serious or Rare Side Effects: - Severe dehydration: marked fluid loss requiring medical attention. - Significant electrolyte disturbances: hypernatremia or hypokalemia that may affect cardiac function. - Renal impairment: reduced kidney function in susceptible individuals. - Allergic reaction: rash, itching, or anaphylaxis. - Colonic perforation: rare but life‑threatening bowel injury.

Before prescribing Moviprep, clinicians should consider patient‑specific factors and monitor for potential complications. - Renal function assessment: evaluate kidney health, especially in patients with chronic kidney disease. - Electrolyte monitoring: check serum sodium and potassium levels prior to and after preparation. - Contraindication in bowel obstruction: avoid use when mechanical blockage is present. - Caution in severe dehydration: ensure adequate hydration before administration. - Elderly patients: start with lower volume and monitor tolerance closely. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Moviprep can interact with other agents that affect fluid and electrolyte balance.

Major Interactions (Avoid): - Loop diuretics: may exacerbate dehydration and electrolyte loss. - Potassium‑sparing diuretics: increase risk of hyperkalemia. - ACE inhibitors or ARBs: can potentiate renal impairment when combined with volume depletion.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect renal function, requiring closer monitoring. - Lithium: altered lithium levels due to changes in renal clearance. - Antacids containing magnesium or aluminum: may affect absorption of electrolytes. - Oral rehydration solutions: coordinate timing to avoid excessive fluid intake.